Welcome to The Intel, the Visiopharm Newsletter that brings you our latest news and digital pathology content each month. Here are the highlights of this month:
New HER2 algorithm - a fully automated single-cell approach for whole slide HER2 IHC quantification aligned with ASCO/CAP guidelines.
New integration—built for pathologists and loved by PACS/IMS admins.
How much valuable data can you unlock from a single multiplex image? Explore the full potential by diving into our Phenoplex whitepaper.
Highlighted publication: A best practices framework for spatial biology studies.
As always, feel free to get in touch if you have any questions or would like to book a demo. You can also check out our Resources page for the latest guides, posters and webinars.
Discover our new HER2 algorithm
A fully automated single-cell approach for whole slide HER2 IHC quantification aligned with ASCO/CAP guidelines.
Recent advancements in antibody-drug conjugates (ADCs) have introduced more nuanced classifications to HER2 IHC scoring, like HER2-low (1+ and 2+ without gene amplification) and even HER2-ultralow (detectable but less than 1+). These classifications, supported by clinical trials such as DESTINY-Breast04 and DESTINY-Breast06, expand treatment options to include therapies like trastuzumab deruxtecan (TDXd) for a broader range of patients.
How does our new HER2 algorithm* fit in?
The new APP offers a nuanced and detailed analysis of HER2 expression, allowing pathologists to more confidently identify HER2-low and HER2-ultralow cases while optimizing the 2+-rate to limit expensive reflex testing.
Our reference lab, UMC Utrecht, conducted a comprehensive business case analysis, revealing that the use of Visiopharm’s AI APP results in a positive business case with a significant return on investment. These savings are indicative of the efficiency and financial benefits that AI technology can bring to pathology departments.
How much valuable data can you extract from a single multiplex image?
Our research team conducted an in-depth analysis of a 30-plex image using Phenoplex, showcasing the multiple ways you can use this powerful tool to improve our understanding of tumor and disease biology.
A best practices framework for spatial biology studies in drug discovery and development: enabling successful cohort studies using digital spatial profiling
Krull, D., Haynes, P., Kesarwani, A., Tessier, J., et al. published a best-practices framework for spatial biology studies using GeoMx DSP. The authors demonstrate how digital spatial profiling can be optimized to overcome tissue sample constraints and enhance biomarker discovery. This framework empowers researchers to maximize insights from limited samples in spatial biology.
Visiopharm's Oncotopix® Discovery software was key to the image analysis process, specifically in selecting regions of interest (ROIs) and segmenting tissue compartments for precise analysis.
